Canada - English - Health Canada

pfizer canada inc., consumer healthcare division - magnesium hydroxide; aluminum hydroxide; dimethicone - suspension - 350mg; 650mg; 30mg - magnesium hydroxide 350mg; aluminum hydroxide 650mg; dimethicone 30mg - antacids and adsorbents

Canada - English - Health Canada

pfizer canada inc., consumer healthcare division - magnesium hydroxide; aluminum hydroxide - suspension - 400mg; 400mg - magnesium hydroxide 400mg; aluminum hydroxide 400mg - antacids and adsorbents

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - aluminium hydroxide 80 mg/ml; magnesium hydroxide 80 mg/ml; simeticone 6 mg/ml (added as 20 mg/ml of simeticone emulsion q7-2587 30%) - oral suspension - active: aluminium hydroxide 80 mg/ml magnesium hydroxide 80 mg/ml simeticone 6 mg/ml (added as 20 mg/ml of simeticone emulsion q7-2587 30%) excipient: acesulfame potassium avicel rc-591 benzyl alcohol enhancer flavour fadp925 (natural sweetness) ethanol ethyl hydroxybenzoate mint flavour sn011397 propyl hydroxybenzoate purified water sorbitol triacetin xanthan gum xylitol - relief from indigestion, heartburn, upset stomach, flatulence and wind pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - aluminium hydroxide 40 mg/ml; magnesium hydroxide 40 mg/ml; simeticone 4 mg/ml (added as 17.3 mg/ml of simethicone emulsion q7-2587 30%) - oral suspension - active: aluminium hydroxide 40 mg/ml magnesium hydroxide 40 mg/ml simeticone 4 mg/ml (added as 17.3 mg/ml of simethicone emulsion q7-2587 30%) excipient: acesulfame potassium avicel rc-591 benzyl alcohol enhancer flavour fadp925 (natural sweetness) ethanol ethyl hydroxybenzoate mint flavour sn011397 propyl hydroxybenzoate purified water sorbitol triacetin xanthan gum xylitol - relief from indigestion, heartburn, upset stomach, flatulence and wind pain.

United States - English - NLM (National Library of Medicine)

infirst healthcare inc. - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o), magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838) - antacid antacid anti-gas relieves: • heartburn • acid indigestion • sour stomach • upset stomach due to these symptoms • pressure and bloating commonly referred to as gas • overindulgence in food and drink

United States - English - NLM (National Library of Medicine)

infirst healthcare inc. - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o), magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838) - antacid antacid anti-gas relieves: • heartburn • acid indigestion • sour stomach • upset stomach due to these symptoms • pressure and bloating commonly referred to as gas • overindulgence in food and drink

United States - English - NLM (National Library of Medicine)

p & l development, llc - aluminum hydroxide (equivalent to dried gel, usp) 200 mg magnesium hydroxide 200 mg simethicone 20 mg -

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 100 mg - gabapentin capsules, usp are indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin capsules, usp are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy category c : there are no adequate and well-controlled studies in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic when administered to pregnant animals at doses similar to or lower than those used clinically. gabapentin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. when pregnant mice received oral doses of gabapentin (500 mg, 1000 mg, or 3000 mg/kg/day) during the period of organogenesis, embryo-fetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 400 mg - gabapentin capsules, usp are indicated for: gabapentin capsules, usp are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy category c : there are no adequate and well-controlled studies in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic when administered to pregnant animals at doses similar to or lower than those used clinically. gabapentin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. when pregnant mice received oral doses of gabapentin (500 mg, 1000 mg, or 3000 mg/kg/day) during the period of organogenesis, embryo-fetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no-effect dose for embryo-fetal developmental toxicity in mice was 500 mg/kg/day or approximately ½ of the maximum recommended human dose (mrhd) of 3600 mg/kg on a body surface area (mg/m2 ) basis. in studies in which rats r

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 300 mg - gabapentin capsules, are indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin capsules are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy category c : there are no adequate and well-controlled studies in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic when administered to pregnant animals at doses similar to or lower than those used clinically. gabapentin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. when pregnant mice received oral doses of gabapentin (500 mg, 1000 mg, or 3000 mg/kg/day) during the period of organogenesis, embryo-fetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no-effect d